| GRg1 inhibits the TLR4/NF-kB signaling pathway by upregulating miR-216a-5p to reduce growth factors and inflammatory cytokines in DR. | GRg1 inhibits the TLR4/NF-kB signaling pathway by upregulating miR-216a-5p to reduce growth factors and inflammatory cytokines in DR.
Xue L, Hu M, Zhu Q, Li Y, Zhou G, Zhang X, Zhou Y, Zhang J, Ding P., Free PMC Article | 03/19/2024 |
| Expression of TLE-1 in Gastrointestinal Stromal Tumour and Its Relationship to Clinicopathological Parameters. | Expression of TLE-1 in Gastrointestinal Stromal Tumour and Its Relationship to Clinicopathological Parameters.
Hasbay B, kayaselCuk F. | 03/27/2023 |
| Prognostic Value of TLE1 Gene Expression in Patients with T-cell Acute Lymphoblastic Leukemia. | Prognostic Value of TLE1 Gene Expression in Patients with T-cell Acute Lymphoblastic Leukemia.
Aref S, El-Ghonemy MS, Atia DM, Elbaiomy MM, Abdelsalam SA, Tawfik A, El-Sebaie A., Free PMC Article | 11/27/2021 |
| Tissue microarray based immunohistochemical study of TLE1 in synovial sarcoma and its histologic mimics. | Tissue microarray based immunohistochemical study of TLE1 in synovial sarcoma and its histologic mimics.
Sivakoti S, Uppin SG, Uppin MS, Tara RP, Prayaga AK, Challa S. | 10/9/2021 |
| lncRNA RASSF8AS1 suppresses the progression of laryngeal squamous cell carcinoma via targeting the miR664b3p/TLE1 axis. | lncRNA RASSF8‑AS1 suppresses the progression of laryngeal squamous cell carcinoma via targeting the miR‑664b‑3p/TLE1 axis.
Liu T, Meng W, Cao H, Chi W, Zhao L, Cui W, Yin H, Wang B., Free PMC Article | 07/10/2021 |
| Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site. | Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site.
Kornspan D, Smith Y, Nechushtan H. | 05/15/2021 |
| Gene of the month: TLE 1. | Gene of the month: TLE 1.
Pinto K, Chetty R. | 03/20/2021 |
| SATB2 and TLE1 Expression in BCOR-CCNB3 (Ewing-like) Sarcoma, Mimicking Small Cell Osteosarcoma and Poorly Differentiated Synovial Sarcoma. | SATB2 and TLE1 Expression in BCOR-CCNB3 (Ewing-like) Sarcoma, Mimicking Small Cell Osteosarcoma and Poorly Differentiated Synovial Sarcoma.
Creytens D. | 11/28/2020 |
| TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans. | TLE1 expression fails to distinguish between synovial sarcoma, atypical fibroxanthoma, and dermatofibrosarcoma protuberans.
Pukhalskaya T, Smoller BR. | 10/10/2020 |
| The combined use of H3K27 trimethylation and TLE1 can provide additional diagnostic value for malignant peripheral nerve sheath tumor and synovial sarcoma. | The combined use of H3K27 trimethylation and TLE1 can provide additional diagnostic value for malignant peripheral nerve sheath tumor and synovial sarcoma.
Khalil EZI, Osman NAA. | 10/3/2020 |
| These data support TLE1 as a putative regulator of human beta-cell identity, with dysregulated expression in T2D associated with increased glucagon expression potentially reflecting beta- to alpha-cell conversion. | Reduced Expression of the Co-regulator TLE1 in Type 2 Diabetes Is Associated with Increased Islet α-Cell Number.
Armour SL, Anderson SJ, Richardson SJ, Ding Y, Carey C, Lyon J, Maheshwari RR, Al-Jahdami N, Krasnogor N, Morgan NG, MacDonald P, Shaw JAM, White MG. | 08/1/2020 |
| The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma. | The Utility of NKX2.2 and TLE1 Immunohistochemistry in the Differentiation of Ewing Sarcoma and Synovial Sarcoma.
Rooper LM, Sharma R, Gocke CD, Belchis DA. | 04/18/2020 |
| Nuclear TLE1 expression was identified in 24 (57%) of the 42 melanoma cases with spindle cell morphology. TLE1 frequently highlights melanomas with spindle cell morphology and is a potential diagnostic pitfall. When evaluating spindle cell tumors in which the differential may include both a melanoma and synovial sarcoma, TLE1 expression should be interpreted with caution. | Expression of TLE1 in Malignant Melanoma With Spindle Cell Morphology: A Potential Diagnostic Pitfall.
Morrell TJ, Xiong Y, Deng A, Dresser K, O'Donnell P, Cornejo KM. | 08/31/2019 |
| These results provide previously unavailable insight into the transcriptional programs underlying the tumour-promoting functions of FOXG1:TLE1 in glioblastoma. | Characterization of a FOXG1:TLE1 transcriptional network in glioblastoma-initiating cells.
Dali R, Verginelli F, Pramatarova A, Sladek R, Stifani S., Free PMC Article | 05/18/2019 |
| These data are of particular interest and give support for a plausible role of TLE1 as a tumor suppressor in T-cell ALL. Moreover, the prognostic value of this corepressor may assist ALL treatment stratification and suggest the need of alternative regimens. | TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
Brassesco MS, Pezuk JA, Cortez MA, Bezerra Salomão K, Scrideli CA, Tone LG. | 05/18/2019 |
| There is frequent expression of TLE1 in cutaneous neoplasms, including sebaceous neoplasms, basal cell carcinoma, and squamous cell carcinomas. | Frequent TLE1 Expression in Cutaneous Neoplasms.
Xiong Y, Dresser K, Cornejo KM. | 04/27/2019 |
| Using trio-based exome sequencing, we identified a homozygous missense mutation in the Transducin-like enhancer of split-1 (TLE1) gene, encoding for a non DNA-binding transcriptional corepressor, highly expressed in the postnatal brain | TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly.
Cavallin M, Maillard C, Hully M, Philbert M, Boddaert N, Reilly ML, Nitschké P, Bery A, Bahi-Buisson N. | 02/23/2019 |
| Case Report: primary subcutaneous biphasic synovial sarcoma with TlE1 immunoreactivity. | Primary Subcutaneous Synovial Sarcoma: First Reported Subcutaneous Case Showing TLE1 Immunoreactivity.
Alegría-Landa V, Nájera L, Massa DS, Roustan G, Río MD, Kutzner H, Requena L. | 01/12/2019 |
| The majority of malignant rhabdoid tumors and atypical teratoid/rhabdoid tumor cases showed some TLE1 immunoreactivity (n = 16; 89% for >/=1 + staining); 14 (78%) of total cases showed >/=2 + positivity using any of the 3 scoring systems. Over half (n = 10; 56%) of cases showed >/=2 + staining; 4 (22%) cases showed 3 + strong and diffuse TLE1 staining measured by all scoring systems in agreement. | TLE1 Expression in Malignant Rhabdoid Tumor and Atypical Teratoid/Rhabdoid Tumor.
Duncan VE, Wicker JA, Kelly DR, Li R. | 12/22/2018 |
| Immunohistochemical analysis for TLE1 can identify basal cell adenomas and basal cell adenocarcinomas by luminal cell staining difference, especially indistinct luminal cell expression for TLE1 in invasive areas of BCAC. | Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study.
Oyama Y, Nishida H, Kusaba T, Kadowaki H, Arakane M, Wada J, Urabe S, Hirano T, Kawano K, Suzuki M, Yokoyama S, Daa T., Free PMC Article | 12/22/2018 |
| TLE1 is a potential immunohistochemical marker for glomus tumors | Transducing-Like Enhancer of Split 1: A Potential Immunohistochemical Marker for Glomus Tumor.
Bozdogan N, Dilek GB, Benzer E, Karadeniz M, Bozdogan O. | 04/14/2018 |
| studies indicate Bit1 is an inhibitor of EMT and metastasis in lung cancer and hence can serve as a molecular target in curbing lung cancer aggressiveness | The Anoikis Effector Bit1 Inhibits EMT through Attenuation of TLE1-Mediated Repression of E-Cadherin in Lung Cancer Cells.
Yao X, Pham T, Temple B, Gray S, Cannon C, Chen R, Abdel-Mageed AB, Biliran H., Free PMC Article | 02/17/2018 |
| Authors present data indicating that TLE1 is rapidly excluded from the nucleus following epidermal growth factor receptor pathway activation, an effect that likely accounts for its inability to mediate effective repression under such conditions. | Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function.
Zahavi T, Maimon A, Kushnir T, Lange R, Berger E, Kornspan D, Grossman R, Anzi S, Shaulian E, Karni R, Nechushtan H, Paroush Z. | 10/14/2017 |
| TLE1 is not a stand-alone diagnostic immunohistochemical marker for synovial sarcoma | Transducer-like enhancer of split 1 (TLE1) expression as a diagnostic immunohistochemical marker for synovial sarcoma and its association with morphological features.
Bakrin IH, Hussain FA, Tuan Sharif SE. | 06/24/2017 |
| Data suggest TLE1 is highly expressed in macrophages cultured in vitro, in macrophages of atherosclerotic plaques, and in macrophages of visceral adipose tissue from obese women; expression of TLE1 is up-regulated upon macrophage activation. | Transducin-like enhancer of split-1 is expressed and functional in human macrophages.
De Paoli F, Copin C, Vanhoutte J, Derudas B, Vinod M, Zawadzki C, Susen S, Pattou F, Haulon S, Staels B, Eeckhoute J, Chinetti-Gbaguidi G. | 08/13/2016 |